Gliknik
Baltimore, US · Delaware corporation · 2 known investors
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
Biotech
Founders & leadership
DS
David S. BlockFounder
EC
Elizabeth C. BlockExecutive
RS
Raymond ShinaziNamed on SEC filing
JK
Joseph KleinNamed on SEC filing
EB
Elizabeth BlockNamed on SEC filing
ML
Mark LernerNamed on SEC filing
Board
CP
Charles PolskyBoard director
DB
David BroserBoard director
RS
Raymond SchinaziBoard director
KR
RL
Richard LevyBoard director
PA
Paul A. FriedmanBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$29.8M disclosed across 4 rounds · 2021–2025
▶$11MraisedAug 2025 · 9 investors · BiotechnologyRule 506(b)
▶$11MraisedAug 2025 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David S. BlockExecutive Officer, Director
- Richard LevyDirector
- Charles PolskyDirector
- Elizabeth BlockExecutive Officer
- Raymond SchinaziDirector
- Paul FreidmanDirector
- David BroserDirector
- Kyle RusconiDirector
- Offering amount
- $15M
- Amount sold
- $11M
- Proceeds to insiders
- $565K
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.3MraisedJan 2025 · 25 investors · BiotechnologyRule 506(b)
▶$5.3MraisedJan 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Charles PolskyDirector
- David BroserDirector
- Richard LevyDirector
- Paul A. FriedmanDirector
- David S. BlockExecutive Officer, Director
- Raymond SchinaziDirector
- Elizabeth C. BlockExecutive Officer
- Kyle RusconiDirector
- Offering amount
- $6M
- Amount sold
- $5.3M
- Proceeds to insiders
- $500K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.2MraisedMar 2024 · 23 investors · BiotechnologyRule 506(b)
▶$9.2MraisedMar 2024 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott Eric StromeDirector
- Richard S. LevyDirector
- David S. BlockExecutive Officer, Director
- Paul A. FriedmanDirector
- David BroserDirector
- Kyle J. RusconiDirector
- Charles V. PolskyDirector
- Raymond F. SchinaziDirector
- Elizabeth C. BlockExecutive Officer
- Mark D. LernerDirector
- Offering amount
- $16.2M
- Amount sold
- $9.2M
- Proceeds to insiders
- $500K
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.3MraisedJun 2021 · 4 investors · BiotechnologyRule 506(b)
▶$4.3MraisedJun 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Raymond ShinaziDirector
- Joseph KleinDirector
- Elizabeth BlockExecutive Officer
- David S. BlockExecutive Officer, Director
- Richard LevyDirector
- Mark LernerDirector
- Paul A. FriedmanDirector
- Offering amount
- $12M
- Amount sold
- $4.3M
- Minimum investment
- $25K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Gliknik for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Gliknik do?
- Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
- Who founded Gliknik?
- Gliknik was founded by David S. Block.
- Who are Gliknik's investors?
- Gliknik's investors include Brace Pharma, First In Ventures.
- How much funding has Gliknik raised?
- Gliknik has disclosed $29.8M raised across 4 rounds.
- Where is Gliknik headquartered?
- Gliknik is headquartered in Baltimore, US.